Armata Pharmaceuticals Current Valuation vs. Net Income
| ARMP Stock | USD 10.44 0.19 1.79% |
For Armata Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Armata Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Armata Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Armata Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Armata Pharmaceuticals over time as well as its relative position and ranking within its peers.
Check out Trending Equities. Can Biotechnology industry sustain growth momentum? Does Armata have expansion opportunities? Factors like these will boost the valuation of Armata Pharmaceuticals. If investors know Armata will grow in the future, the company's valuation will be higher. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Armata Pharmaceuticals demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (1.66) | Revenue Per Share | Quarterly Revenue Growth (0.61) | Return On Assets | Return On Equity |
Armata Pharmaceuticals's market price often diverges from its book value, the accounting figure shown on Armata's balance sheet. Smart investors calculate Armata Pharmaceuticals' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Since Armata Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Armata Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Armata Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Armata Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Armata Pharmaceuticals Net Income vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Armata Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Armata Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Armata Pharmaceuticals is the top company in current valuation category among its peers. It is rated third in net income category among its peers . Armata Pharmaceuticals reported last year Net Loss of (17.02 Million). Comparative valuation analysis is a catch-all technique that is used if you cannot value Armata Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Armata Current Valuation vs. Competition
Armata Pharmaceuticals is the top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is presently estimated at about 1.94 Billion. Armata Pharmaceuticals retains roughly 250.81 Million in current valuation claiming about 13% of equities under Health Care industry.
Armata Net Income vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Armata Pharmaceuticals |
| = | 250.81 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Armata Pharmaceuticals |
| = | (18.92 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Armata Net Income Comparison
Armata Pharmaceuticals is currently under evaluation in net income category among its peers.
Armata Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Armata Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Armata Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Armata Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Armata Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Operating Income | -38.2 M | -36.3 M | |
| Income Before Tax | -17 M | -17.9 M | |
| Total Other Income Expense Net | 27 M | 28.4 M | |
| Net Loss | -17 M | -17.9 M | |
| Income Tax Expense | -26.1 K | -24.8 K | |
| Interest Income | 627.3 K | 595.9 K | |
| Net Loss | -33.2 M | -34.9 M | |
| Net Loss | -17 M | -17.9 M | |
| Net Interest Income | -9 M | -8.6 M | |
| Non Operating Income Net Other | 33.4 K | 37.4 K | |
| Change To Netincome | 4.5 M | 3.9 M | |
| Net Loss | (0.47) | (0.49) | |
| Income Quality | 1.79 | 1.07 | |
| Net Income Per E B T | 0.83 | 0.96 |
Armata Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Armata Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Armata Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Armata Pharmaceuticals' important profitability drivers and their relationship over time.
Armata Pharmaceuticals Earnings Estimation Breakdown
The calculation of Armata Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Armata Pharmaceuticals is estimated to be -0.2725 with the future projection ranging from a low of -0.2725 to a high of -0.2725. Please be aware that this consensus of annual earnings estimates for Armata Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.27 Lowest | Expected EPS | -0.27 Highest |
Armata Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Armata Pharmaceuticals' value are higher than the current market price of the Armata Pharmaceuticals stock. In this case, investors may conclude that Armata Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Armata Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 2 | 43.04% | 0.0 | -0.2725 | -1.66 |
Armata Pharmaceuticals Earnings per Share Projection vs Actual
Actual Earning per Share of Armata Pharmaceuticals refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Armata Pharmaceuticals predict the company's earnings will be in the future. The higher the earnings per share of Armata Pharmaceuticals, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Armata Pharmaceuticals Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Armata Pharmaceuticals, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Armata Pharmaceuticals should always be considered in relation to other companies to make a more educated investment decision.Armata Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Armata Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
2025-11-12 | 2025-09-30 | -0.5 | -0.74 | -0.24 | 48 | ||
2025-08-12 | 2025-06-30 | -0.39 | -0.45 | -0.06 | 15 | ||
2025-05-05 | 2025-03-31 | -0.38 | -0.1973 | 0.1827 | 48 | ||
2025-03-19 | 2024-12-31 | -0.35 | -0.2317 | 0.1183 | 33 | ||
2024-11-12 | 2024-09-30 | -0.28 | -0.15 | 0.13 | 46 | ||
2024-08-13 | 2024-06-30 | -0.44 | 0.25 | 0.69 | 156 | ||
2024-05-07 | 2024-03-31 | -0.31 | -0.69 | -0.38 | 122 | ||
2024-03-21 | 2023-12-31 | -0.35 | -0.55 | -0.2 | 57 | ||
2023-11-14 | 2023-09-30 | -0.31 | -0.75 | -0.44 | 141 | ||
2023-08-14 | 2023-06-30 | -0.37 | -0.1 | 0.27 | 72 | ||
2023-05-11 | 2023-03-31 | -0.32 | -0.4 | -0.08 | 25 | ||
2023-03-16 | 2022-12-31 | -0.28 | -0.29 | -0.01 | 3 | ||
2022-11-09 | 2022-09-30 | -0.28 | -0.24 | 0.04 | 14 | ||
2022-08-11 | 2022-06-30 | -0.23 | -0.26 | -0.03 | 13 | ||
2022-05-12 | 2022-03-31 | -0.21 | -0.3 | -0.09 | 42 | ||
2022-03-17 | 2021-12-31 | -0.28 | -0.23 | 0.05 | 17 | ||
2021-11-10 | 2021-09-30 | -0.26 | -0.22 | 0.04 | 15 | ||
2021-08-12 | 2021-06-30 | -0.26 | -0.25 | 0.01 | 3 | ||
2021-05-13 | 2021-03-31 | -0.32 | -0.27 | 0.05 | 15 | ||
2021-03-18 | 2020-12-31 | -0.29 | -0.36 | -0.07 | 24 | ||
2020-11-12 | 2020-09-30 | -0.24 | -0.31 | -0.07 | 29 | ||
2020-08-13 | 2020-06-30 | -0.37 | -0.26 | 0.11 | 29 | ||
2020-05-14 | 2020-03-31 | -0.29 | -0.49 | -0.2 | 68 | ||
2020-03-19 | 2019-12-31 | -0.72 | -0.48 | 0.24 | 33 | ||
2019-11-12 | 2019-09-30 | -0.45 | -0.73 | -0.28 | 62 | ||
2019-08-14 | 2019-06-30 | -0.36 | -0.56 | -0.2 | 55 | ||
2019-05-06 | 2019-03-31 | -1.54 | -1.54 | 0.0 | 0 | ||
2019-03-25 | 2018-12-31 | -0.98 | -2.1 | -1.12 | 114 | ||
2018-11-08 | 2018-09-30 | -1.4 | -1.4 | 0.0 | 0 | ||
2018-08-09 | 2018-06-30 | -2.8 | -2.66 | 0.14 | 5 | ||
2018-05-15 | 2018-03-31 | -2.66 | -3.36 | -0.7 | 26 | ||
2018-03-14 | 2017-12-31 | -5.04 | -3.5 | 1.54 | 30 | ||
2017-11-14 | 2017-09-30 | -6.02 | -1.26 | 4.76 | 79 | ||
2017-05-15 | 2017-03-31 | -114.8 | -27.16 | 87.64 | 76 | ||
2017-03-27 | 2016-12-31 | -42 | 0.42 | 42.42 | 101 | ||
2016-11-10 | 2016-09-30 | -57.4 | -44.8 | 12.6 | 21 | ||
2016-08-15 | 2016-06-30 | -92.4 | -64.4 | 28.0 | 30 | ||
2016-05-12 | 2016-03-31 | -95.2 | -148.4 | -53.2 | 55 | ||
2016-03-30 | 2015-12-31 | -56 | -99.4 | -43.4 | 77 | ||
2015-11-16 | 2015-09-30 | 5.6 | -221.2 | -226.8 | 4050 | ||
2015-08-13 | 2015-06-30 | -140 | -79.8 | 60.2 | 43 | ||
2015-05-15 | 2015-03-31 | 210 | -140.0 | -350.0 | 166 | ||
2014-11-14 | 2014-09-30 | 280 | -70.0 | -350.0 | 125 | ||
2014-05-20 | 2014-03-31 | -140 | -420.0 | -280.0 | 200 | ||
2008-11-05 | 2008-09-30 | -910 | -910.0 | 0.0 | 0 | ||
2008-08-06 | 2008-06-30 | -1190 | -1330.0 | -140.0 | 11 | ||
2008-05-07 | 2008-03-31 | -2100 | -1190.0 | 910.0 | 43 | ||
2008-03-25 | 2007-12-31 | -1120 | -1820.0 | -700.0 | 62 | ||
2007-10-31 | 2007-09-30 | -1820 | -1050.0 | 770.0 | 42 | ||
2007-08-07 | 2007-06-30 | -1190 | -2170.0 | -980.0 | 82 | ||
2007-05-09 | 2007-03-31 | -2100 | -2100.0 | 0.0 | 0 | ||
2007-03-29 | 2006-12-31 | -910 | 560.0 | 1470.0 | 161 | ||
2006-11-08 | 2006-09-30 | -1890 | -2240.0 | -350.0 | 18 | ||
2006-03-09 | 2005-12-31 | -4200 | -2800.0 | 1400.0 | 33 | ||
2005-11-03 | 2005-09-30 | -4200 | -4900.0 | -700.0 | 16 | ||
2005-07-28 | 2005-06-30 | -4200 | -4200.0 | 0.0 | 0 | ||
2005-04-26 | 2005-03-31 | -3850 | -3500.0 | 350.0 | 9 | ||
2005-03-03 | 2004-12-31 | -3266.67 | -2100.0 | 1166.67 | 35 | ||
2004-11-04 | 2004-09-30 | -3500 | -2100.0 | 1400.0 | 40 | ||
2004-07-29 | 2004-06-30 | -3500 | -3500.0 | 0.0 | 0 | ||
2004-04-28 | 2004-03-31 | -3500 | -4900.0 | -1400.0 | 40 | ||
2004-03-01 | 2003-12-31 | -4550 | -7000.0 | -2450.0 | 53 | ||
2003-10-30 | 2003-09-30 | -4900 | -700.0 | 4200.0 | 85 | ||
2003-07-31 | 2003-06-30 | -3500 | -9100.0 | -5600.0 | 160 | ||
2002-04-30 | 2002-03-31 | -11900 | -10500.0 | 1400.0 | 11 | ||
2002-02-14 | 2001-12-31 | -10266.67 | -13300.0 | -3033.33 | 29 | ||
2001-11-09 | 2001-09-30 | -10500 | -11200.0 | -700.0 | 6 | ||
2001-08-14 | 2001-06-30 | -11200 | -9800.0 | 1400.0 | 12 | ||
2001-05-10 | 2001-03-31 | -9800 | -7700.0 | 2100.0 | 21 | ||
2001-03-02 | 2000-12-31 | -11900 | -9800.0 | 2100.0 | 17 | ||
2000-12-15 | 2000-09-30 | 700 | 700.0 | 0.0 | 0 | ||
2000-08-09 | 2000-06-30 | -6650 | -8400.0 | -1750.0 | 26 | ||
2000-05-08 | 2000-03-31 | -7000 | -6300.0 | 700.0 | 10 | ||
1999-02-18 | 1998-12-31 | -10500 | 3500.0 | 14000.0 | 133 | ||
1997-07-31 | 1997-06-30 | -11900 | -13300.0 | -1400.0 | 11 | ||
1997-05-01 | 1997-03-31 | -11200 | -11900.0 | -700.0 | 6 | ||
1997-02-13 | 1996-12-31 | -11900 | -11200.0 | 700.0 | 5 | ||
1996-08-01 | 1996-06-30 | -18900 | -15400.0 | 3500.0 | 18 | ||
1996-05-02 | 1996-03-31 | -17500 | -16100.0 | 1400.0 | 8 | ||
1996-02-13 | 1995-12-31 | -9450 | -13300.0 | -3850.0 | 40 | ||
1995-11-02 | 1995-09-30 | -5600 | -13300.0 | -7700.0 | 137 | ||
1995-08-03 | 1995-06-30 | -22750 | -18900.0 | 3850.0 | 16 | ||
1995-02-09 | 1994-12-31 | -20300 | -17500.0 | 2800.0 | 13 | ||
1994-11-03 | 1994-09-30 | -18900 | -17500.0 | 1400.0 | 7 |
Use Armata Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Armata Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Armata Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Armata Pharmaceuticals Pair Trading
Armata Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Armata Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Armata Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Armata Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Armata Pharmaceuticals to buy it.
The correlation of Armata Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Armata Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Armata Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Armata Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Armata Pharmaceuticals position
In addition to having Armata Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Power Assets Thematic Idea Now
Power Assets
Large capitalization equities showing high long-term performance indicators and above average return expectations based on Macroaxis rating system. The Power Assets theme has 49 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Power Assets Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Armata Stock Analysis
When running Armata Pharmaceuticals' price analysis, check to measure Armata Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Armata Pharmaceuticals is operating at the current time. Most of Armata Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Armata Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Armata Pharmaceuticals' price. Additionally, you may evaluate how the addition of Armata Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.